148 related articles for article (PubMed ID: 26432713)
1. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia.
Alfaraj WA; Cachia D; Tummala S; Thomas SK; Manasanch EE
Ann Hematol; 2016 Jan; 95(2):347-8. PubMed ID: 26432713
[No Abstract] [Full Text] [Related]
2. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
Treon SP; Tripsas CK; Meid K; Kanan S; Sheehy P; Chuma S; Xu L; Cao Y; Yang G; Liu X; Patterson CJ; Warren D; Hunter ZR; Turnbull B; Ghobrial IM; Castillo JJ
Blood; 2014 Jul; 124(4):503-10. PubMed ID: 24859363
[TBL] [Abstract][Full Text] [Related]
3. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
Kersten MJ; Amaador K; Minnema MC; Vos JMI; Nasserinejad K; Kap M; Kastritis E; Gavriatopoulou M; Kraan W; Chamuleau MED; Deeren D; Tick LW; Doorduijn JK; Offner F; Böhmer LH; Liu RD; Pals ST; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):40-51. PubMed ID: 34388022
[TBL] [Abstract][Full Text] [Related]
4. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia.
Noronha V; Fynan TM; Duffy T
J Clin Oncol; 2006 Jan; 24(1):e3. PubMed ID: 16382111
[No Abstract] [Full Text] [Related]
5. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia.
Jonas BA; Fisch SC; Rosenberg AS; Hoeg RT; Tuscano JM; Abedi M
Am J Hematol; 2021 Apr; 96(4):E114-E117. PubMed ID: 33476436
[No Abstract] [Full Text] [Related]
6. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
7. Rituximab plus cyclophosphamide and dexamethasone
Xiong W; Lyu R; Yu Y; Wang T; Yan Y; Wang Y; Liu W; An G; Deng S; Xu Y; Sui W; Huang W; Zou D; Wang J; Qiu L; Yi S
Haematologica; 2024 May; 109(5):1614-1618. PubMed ID: 38205507
[No Abstract] [Full Text] [Related]
8. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia.
Chaudhry M; Steiner R; Claussen C; Patel K; Lee H; Weber D; Thomas S; Feng C; Amini B; Orlowski R; Feng L; Manasanch EE
Leuk Lymphoma; 2019 Apr; 60(4):964-970. PubMed ID: 30227761
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
[TBL] [Abstract][Full Text] [Related]
10. Waldenström's macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125.
Eulitt P; Fabian D; Kelly C; Hemminger J; William BM
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):54-59. PubMed ID: 28390215
[TBL] [Abstract][Full Text] [Related]
11. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA; Tedeschi A; Trotman J; García-Sanz R; Macdonald D; Leblond V; Mahe B; Herbaux C; Tam C; Orsucci L; Palomba ML; Matous JV; Shustik C; Kastritis E; Treon SP; Li J; Salman Z; Graef T; Buske C;
N Engl J Med; 2018 Jun; 378(25):2399-2410. PubMed ID: 29856685
[TBL] [Abstract][Full Text] [Related]
12. Agranulocytosis Associated with Waldenström Macroglobulinemia.
Vaxman I; Shepshelovich D; Hayman L; Raanani P; Lahav M
Acta Haematol; 2018; 140(1):42-45. PubMed ID: 30114687
[TBL] [Abstract][Full Text] [Related]
13. Severe neuropathy in a patient with Waldenstrom disease: from a challenging diagnosis to clinical improvement by innovative therapy.
Bertazzoni P; Andreola G; Laszlo D; Agazzi A; Bassi S; Gigli F; Martinelli G
Leuk Lymphoma; 2006 Sep; 47(9):1970-2. PubMed ID: 17065016
[No Abstract] [Full Text] [Related]
14. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
[TBL] [Abstract][Full Text] [Related]
15. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
Castillo JJ; Meid K; Gustine JN; Dubeau T; Severns P; Hunter ZR; Yang G; Xu L; Treon SP
Clin Cancer Res; 2018 Jul; 24(14):3247-3252. PubMed ID: 29661775
[No Abstract] [Full Text] [Related]
16. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E; Gavriatopoulou M; Kyrtsonis MC; Roussou M; Hadjiharissi E; Symeonidis A; Repoussis P; Michalis E; Delimpasi S; Tsatalas K; Tsirigotis P; Vassou A; Vervessou E; Katodritou E; Gika D; Terpos E; Dimopoulos MA
Blood; 2015 Sep; 126(11):1392-4. PubMed ID: 26359434
[No Abstract] [Full Text] [Related]
17. Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation.
Migkou M; Fotiou D; Gavriatopoulou M; Dimopoulos MA
Expert Opin Drug Saf; 2021 Sep; 20(9):987-995. PubMed ID: 34137347
[No Abstract] [Full Text] [Related]
18. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Grunenberg A; Buske C
Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
[TBL] [Abstract][Full Text] [Related]
19. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
20. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
